CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Selventa’s Systems Diagnostics, or SysDx, will be a novel class of diagnostic tests that consist of “multi-omic” biomarkers selected through analysis of a patient’s biological profile, including genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical record information. From the data, Selventa will generate a differentiated and clinically relevant report that physicians and patients can use to improve therapy selection.
The company is focusing on autoimmune disease and cancer in developing its SysDx tests. These complex multifactorial diseases require more than genetic information alone to obtain an effective diagnosis to guide treatment.
Selventa has achieved proof of concept for multiple SysDx tests in rheumatoid arthritis (RA), inflammatory bowel disease, Crohn’s disease, ulcerative colitis, and multiple cancers.
The company’s lead product will be Clarify-RA, a SysDx test that will predict which patients suffering from RA will not respond to anti-TNF therapy.
Selventa, 617-547-5421